Stock Ratings / Health Care / SEER / options

QTRX (22) HBIO (47) RPID (34) LAB (27) ⌘ Pro Terminal →

Seer Inc. (Class A) (SEER) Options Positioning, Max Pain & Unusual Sweeps

Q: Where is SEER trading relative to its 50-day, 200-day, and 52-week technical levels?

SEER last traded at $1.68 (-13.40% on volume of 516,545 shares), positioning the stock -16.00% below its 50-day simple moving average ($2.00) and -12.50% below its 200-day simple moving average ($1.92). Across its 52-week range of $1.55 to $2.38, SEER sits at the 15.7% percentile with a 14-day RSI of 36.4 (NEUTRAL RANGE) and an implied next-earnings move of ±11.3% ($1.49 to $1.87).

Q: What is SEER's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for SEER.

$1.68 -13.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.64

Seer Inc. (Class A) (SEER) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $93.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SEER Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SEER stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Seer Inc. (Class A) (NASDAQ: SEER) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $1.68 (-13.40% 1D, market cap $93.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SEER ranks #911 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SEER compare to QTRX and HBIO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), SEER carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 51.1%, and ROIC of -29.1%. By comparison, QTRX (Quanterix Corporation) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $137.4M) and HBIO (Harvard Bioscience Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $40.5M). Among the 5-stock peer group, SEER leads on earnings multiple (N/A) while LAB leads on capital efficiency (-28.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SEER?

▼

Per SEER's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001726445), Seer Inc. (Class A) generated $16.6M in revenue (+17.0% YoY), -$73.6M in net income, and -$46.2M in free cash flow against $296.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.64 (-2.60%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-14.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SEER)Realized 20D OHLCV Swing Band: ±11.3%

Deterministic 5-Pillar Attribution (26/100 Composite)

🔍 WHY SEER SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (31% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (27% of score)

FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 36.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.11-6.2% Next Q

Q2 (-2Q)

Grade E$1.98-1% Next Q

Q3 (-1Q)

Grade E$1.96-14.3% Next Q

Current

Grade E$1.68-10.5% Hist 90D α

Trajectory: E (34) → E (26)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SEER Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SEER currently carries a cautious 26/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.00) and Max Pain ($1.76) forces dealer call-delta covering toward $2.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SEER• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SEER Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 26%NO 74%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±11.3%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (SEER)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for SEER.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SEER)

✓Walkthrough of SEER's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SEER // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.85%🛡️ HOLDING TREND SUPPORT

2026-11-03O $1.94H $1.94L $1.68C $1.68VOL 516.5K

RES: $2.44SUP: $1.61SMA50: $2.00SMA200: $1.92

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SEER Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SEER Butterfly Map → + Track SEER →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +17.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SEER today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SEER. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SEER today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SEER)

Health Care Rank #911 of 1016 ⚔️ QTRX vs SEER Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SEER vs. QTRX, HBIO, RPID, LAB)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Seer Inc. (Class A) (SEER) ranks #911 by composite RQD confidence (26/100, grade E) and #664 by equity capitalization ($93.0M). Within this direct 5-issuer industry benchmark cohort, SEER leads on earnings valuation at N/A trailing P/E, while LAB leads on capital efficiency and profitability with -28.7% ROIC and 49.9% gross margin. HBIO currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with SEER at 26/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SEER ACTIVE Seer Inc. (Class A)	E	26/100	—	51.1%	-29.1%	-13.40%	$93.0M	Benchmark Subject
QTRX Quanterix Corporation	E	22/100	—	46.8%	-35.0%	-7.63%	$137.4M	/qtrx-vs-seer →
HBIO Harvard Bioscience Inc.	D	47/100	—	57.7%	-35.0%	+1.14%	$40.5M	/hbio-vs-seer →
RPID Rapid Micro Biosystems Inc. (Class A)	E	34/100	—	—	-35.0%	-6.73%	$36.9M	/rpid-vs-seer →
LAB Standard BioTools Inc.	E	27/100	—	49.9%	-28.7%	-1.61%	$240.7M	/lab-vs-seer →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001726445

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Seer Inc. (Class A) (SEER) reported GAAP revenue of $16.6M (+17.0% vs. FY2024 revenue of $14.2M , and -0.5% cumulative change since FY2023) , GAAP net income of -$73.6M, operating cash flow of -$44.4M, and free cash flow of -$46.2M (+6.9% YoY). On the balance sheet, SEER closed FY2025 with $296.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$16.6M	-$73.6M	-$44.4M	-$46.2M	$296.1M	—
FY2024 (FY)	2024-12-31	$14.2M	-$86.6M	-$46.1M	-$49.7M	$366.6M	—
FY2023 (FY)	2023-12-31	$16.7M	-$86.3M	-$59.1M	-$59.1M	—	—

3. SEER Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SEER stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SEER compare to QTRX and HBIO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SEER?

Where is SEER trading relative to its 50-day, 200-day, and 52-week technical levels?

SEER last traded at $1.68 (-13.40% on volume of 516,545 shares), positioning the stock -16.00% below its 50-day simple moving average ($2.00) and -12.50% below its 200-day simple moving average ($1.92). Across its 52-week range of $1.55 to $2.38, SEER sits at the 15.7% percentile with a 14-day RSI of 36.4 (NEUTRAL RANGE) and an implied next-earnings move of ±11.3% ($1.49 to $1.87).

SEER Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is SEER's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for SEER.

Direct Sub-Reports: SEER RQD Cockpit SEER 12M Forecast SEER Earnings & Move SEER Dividends & DRIP SEER Insiders & 13F SEER Whale Options SEER Profit Sankey SEER News & Why

ROARABLE RATING BRIEF • RQD 26/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SEER — Seer Inc. (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:43:48Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SEER scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the fundamental cash engine scores 3 of 20 (ROIC -29.1%; FCF yield 0%), indicating the weakest contribution to the rating and reflecting that the business is not currently generating returns on capital or free cash flow. Whale 13F flow scores 8 of 20 and insider conviction scores 5 of 20, meaning the institutional and insider signals provided in the source data offer limited support. Macro regime fit scores 12 of 20 with beta at 1.0, a neutral-to-moderate sensitivity profile. Forensic balance sheet scores 8 of 20, reflecting Altman Z 0.2, Piotroski F 5/9, and Debt/Equity 0.5. For a prospective investor, the upside case rests on any improvement in operating losses, which the source data does not forecast. Valuation tradeoffs are difficult to assess because P/E, forward P/E, EV/EBITDA, and EPS are not available in source data. The reported net margin of -60% and operating margin of -60% mean the company is currently unprofitable on the basis of the market data provided.

Business

Seer Inc. (Class A) (SEER) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry, per the profile section. The source data does not describe the company's specific products, customers, or revenue model. Per the SEC financials, the company reported revenue of $16.6M for FY 2025, $14.2M for FY 2024, and $16.7M for FY 2023. Beyond these reported figures and its sector classification, the source data does not provide further detail on how the company makes money.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$16.6M	$-78.0M	$-73.6M	N/A	$-46.2M	$47.3M	N/A
FY 2024	$14.2M	$-100.1M	$-86.6M	N/A	$-49.7M	$40.8M	N/A
FY 2023	$16.7M	$-103.5M	$-86.3M	N/A	$-59.1M	N/A	N/A

Per the SEC financials, the company reported operating losses in each period shown, narrowing from $-103.5M in FY 2023 to $-78.0M in FY 2025. Per the market data, the gross margin is 51.1%, while operating and net margins are both -60%, and ROIC is -29.1%. The forensic balance sheet metrics in the Roarable RQD rating are an Altman Z-Score of 0.2 and a Piotroski F-Score of 5/9, with Debt/Equity at 0.5. Cash was reported at $47.3M for FY 2025 and $40.8M for FY 2024, while debt is not available in source data for any period.

Recent Catalysts & News Wire Analysis

The news wire contains six headlines, each tagged with a YELLOW light and MARKET WIRE impact label. The headlines are: a Yahoo Finance report titled "Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process"; a Moomoo report on analyst ratings and price targets; a StockInvest.us forecast; a Stock Titan item describing an open letter from Radoff-JEC Group condemning Seer's decision to remain a public company; an Investing.com India report stating that Seer rejected acquisition proposals and cited undervaluation; and a Simply Wall St stock analysis. The source data does not include the full text of these articles, so the specific arguments are not verifiable beyond headline and summary text. The butterfly supply-chain graph reports a supply chain value of NONE, with no butterfly links and no proprietary signals.

Open Questions

What is the company's revenue model, product set, and customer base, given that the source data provides only sector classification and reported revenue totals?
What are the EPS, P/E, and EV/EBITDA figures, which would be required to assess valuation against the reported losses?
What is the company's debt position, since debt is listed as N/A for every reported period while Debt/Equity is cited as 0.5 in the RQD rating?
What were the outcomes of the special committee review and the acquisition proposals referenced in the news wire, and how do they bear on the company's capital structure?
What cash runway does the company have, given cash of $47.3M against FY 2025 free cash flow of $-46.2M?

SEER Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Seer Inc. (Class A) (SEER) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SEER Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 16h ago

Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process

Yahoo Finance report covering Seer Inc. (Class A) (SEER) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 19h ago

SEER TECH (06106) Analyst Ratings, Stock Forecast and Price Target

Moomoo report covering Seer Inc. (Class A) (SEER) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 22h ago

Seer Stock Price Forecast. Should You Buy SEER?

StockInvest.us report covering Seer Inc. (Class A) (SEER) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Radoff-JEC Group Issues Open Letter Condemning Seer’s Unexplained and Seemingly Illogical Decision to Remain a Public Company

Stock Titan report covering Seer Inc. (Class A) (SEER) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com India • 1d ago

Seer rejects acquisition proposals, cites undervaluation By Investing.com

Investing.com India report covering Seer Inc. (Class A) (SEER) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Shanghai Seer Intelligent Technology (SEHK:6106) - Stock Analysis

Simply Wall St report covering Seer Inc. (Class A) (SEER) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Seer stock: Seer announced a CFO transition. Seer stock has November 10 results ahead

ad-hoc-news.de report covering Seer Inc. (Class A) (SEER) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Seer stock: Seer schedules November 10 results. Seer stock posted USD 3.10 million revenue.

ad-hoc-news.de report covering Seer Inc. (Class A) (SEER) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SEER Bull vs. Bear Conversation Board — What's Your Call at $1.68?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SEER 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.71 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SEER (D- • RQD 36/100) a Buy at $1.94?

Welcome to the SEER (Seer Inc. (Class A)) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Laboratory Analytical Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.53 (-21.1%)

Spot @ $1.94

Pump the brakes on SEER — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SEER, but look at what you are paying: current EV/EBITDA multiples with 51.1% gross margins. Unless Seer Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.31 (+19.1%)

Spot @ $1.94

SEER cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SEER, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $1.94 (52-wk range $1.55 - $2.38), any beat on forward guidance forces shorts and underweight funds to chase.